UFP-512

UFP-512 is a highly potent and selective peptide-based agonist of the delta-opioid receptor (DOR). Developed by researchers at the University of Ferrara, it is a peptidomimetic compound designed to exhibit high affinity and efficacy at DOR while maintaining stability. UFP-512 has demonstrated significant neuroprotective, antidepressant, and anxiolytic-like effects in various animal models. In the context of neurodegenerative pathology, specifically Alzheimer's disease, UFP-512 has been shown to ameliorate microglia-induced synapse loss by regulating the classical complement pathway initiator C1q. By binding to C1q and activating DOR, the compound suppresses complement-dependent synaptic engulfment, thereby preserving synaptic proteins and improving cognitive performance in preclinical models.

Other names

H-Dmt-Tic-NH-CH(CH2-COOH)-BidDmt-Tic-NH-CH(CH2-COOH)-Bid